Cargando…

Pre-Antiretroviral Therapy Serum Selenium Concentrations Predict WHO Stages 3, 4 or Death but not Virologic Failure Post-Antiretroviral Therapy

A case-cohort study, within a multi-country trial of antiretroviral therapy (ART) efficacy (Prospective Evaluation of Antiretrovirals in Resource Limited Settings (PEARLS)), was conducted to determine if pre-ART serum selenium deficiency is independently associated with human immunodeficiency virus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shivakoti, Rupak, Gupte, Nikhil, Yang, Wei-Teng, Mwelase, Noluthando, Kanyama, Cecilia, Tang, Alice M., Pillay, Sandy, Samaneka, Wadzanai, Riviere, Cynthia, Berendes, Sima, Lama, Javier R., Cardoso, Sandra W., Sugandhavesa, Patcharaphan, Semba, Richard D., Christian, Parul, Campbell, Thomas B., Gupta, Amita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245580/ https://www.ncbi.nlm.nih.gov/pubmed/25401501 http://dx.doi.org/10.3390/nu6115061

Ejemplares similares

Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort
por: Balagopal, Ashwin, et al.
Publicado: (2016)

Inflammation and micronutrient biomarkers predict clinical HIV treatment failure and incident active TB in HIV-infected adults: a case-control study
por: Shivakoti, Rupak, et al.
Publicado: (2018)

Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings
por: Havers, Fiona P., et al.
Publicado: (2014)

C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings
por: Tenforde, Mark W., et al.
Publicado: (2015)

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial
por: Avihingsanon, Anchalee, et al.
Publicado: (2022)

Pregnancy and Virologic Response to Antiretroviral Therapy in South Africa
por: Westreich, Daniel, et al.
Publicado: (2011)

Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2016)

Predicting virological decay in patients starting combination antiretroviral therapy
Publicado: (2016)

Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
por: Salvi, Sonali, et al.
Publicado: (2022)

Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda
por: Kaleebu, Pontiano, et al.
Publicado: (2015)

Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings
por: Gupta, Amita, et al.
Publicado: (2022)

Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda
por: Tukei, Vincent J, et al.
Publicado: (2013)

Antiretroviral therapy adherence monitoring and its impact on immuno-virological outcome
por: Lobodan, Alina, et al.
Publicado: (2014)

Clinical, immunological, and virological outcomes of pediatric antiretroviral therapy in central China
por: Zheng, Junwen, et al.
Publicado: (2014)

Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland
por: Duong, Trinh, et al.
Publicado: (2014)

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
por: Collins, Sean E., et al.
Publicado: (2015)

Antiretroviral Therapy Program in Ethiopia Benefits From Virology Treatment Monitoring
por: Barnabas, GebreAb, et al.
Publicado: (2017)

1573. Viral Blips While on Antiretroviral Therapy are Associated with Virologic Failure
por: Fleit, Madeline, et al.
Publicado: (2023)

Immunologic status and virologic outcomes in repeat pregnancies to HIV-positive women not on antiretroviral therapy at conception: a case for lifelong antiretroviral therapy?
por: French, Clare E., et al.
Publicado: (2014)

The cost of antiretroviral therapy in Haiti
por: Koenig, Serena P, et al.
Publicado: (2008)

Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring
por: von Wyl, Viktor, et al.
Publicado: (2012)

Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India
por: Gupte, Akshay N., et al.
Publicado: (2019)

Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy
por: Prabhakar, B., et al.
Publicado: (2011)

Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007
por: Ballif, Marie, et al.
Publicado: (2009)

Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia
por: Chkhartishvili, Nikoloz, et al.
Publicado: (2014)

Long-term Virological Outcome in Children on First-line Antiretroviral Therapy in India
por: Chandrasekaran, Padmapriyadarsini, et al.
Publicado: (2017)

Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti
por: Jean Louis, Frantz, et al.
Publicado: (2018)

Long-term virological outcome in children receiving first-line antiretroviral therapy
por: Chandrasekaran, Padmapriyadarsini, et al.
Publicado: (2018)

Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy
por: Bhagwat, Priya, et al.
Publicado: (2019)

Trajectories of Antiretroviral Therapy Adherence and Virologic Failure in Women With HIV in the United States
por: Elbur, Abubaker Ibrahim, et al.
Publicado: (2023)

Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study
por: Loutfy, Mona Rafik, et al.
Publicado: (2013)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission
por: Nyakato, Patience, et al.
Publicado: (2020)

Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti
por: Charles, Macarthur, et al.
Publicado: (2012)

Long-term clinical, immunological and virological outcomes of patients on antiretroviral therapy in southern Myanmar
por: Bermúdez-Aza, Elkin Hernán, et al.
Publicado: (2018)

Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection
por: Bunnell, Kristen L., et al.
Publicado: (2018)

Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy–Experienced Ugandans With Virologic Failure
por: Mpoza, Edward, et al.
Publicado: (2019)

Virological suppression in children and adolescents is not influenced by genotyping, but depends on optimal adherence to antiretroviral therapy
por: Abreu, Juliana Costa de, et al.
Publicado: (2017)

Psychosocial Predictors of Non-Adherence and Treatment Failure in a Large Scale Multi-National Trial of Antiretroviral Therapy for HIV: Data from the ACTG A5175/PEARLS Trial
por: Safren, Steven A., et al.
Publicado: (2014)

CD4(+) and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States
por: Fairlie, Lee, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o3ql4nq22j3q46oefacf560oq2